Registry on the EXperience of Extracorporeal CO2 Removal in Intensive Care Units
Launched by REXECOR · Nov 11, 2016
Trial Information
Current as of May 13, 2025
Unknown status
Keywords
ClinConnect Summary
The registry will be conducted prospectively during 2 years in 10 ICUs of l'APHP on behalf on the CEDIT. The 10 centers are : (1) ICU of l'hôpital europeén Georges Pompidou, (2) ICU of l'Hôpital Louis Mourier, (3) ICU of l'Hôpital de Bicêtre, (4) ICU of GHPS, (5) Respiratory ICU of GHPS, (6) ICU of l'Hôpital Lariboisière (7) ICU of l'Hôpital Cochin (8) ICU of l'Hôpital Saint-Antoine (9)ICU of l'Hôpital Henri Mondor and (10) ICU of l'Hôpital Tenon.
The primary outcome will be the number of patients implanted by ECCO2R monthly in each center during the 2 years period study.
Secondary outcom...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients implanted with ECCCO2R
- Exclusion Criteria:
- • Contra-indication to ECCO2R
About Rexecor
Rexecor is a leading biopharmaceutical company dedicated to advancing innovative therapies for patients with unmet medical needs. Focused on the development of novel treatments across various therapeutic areas, Rexecor leverages cutting-edge research and technology to enhance patient outcomes. With a commitment to rigorous clinical trials and a patient-centric approach, the company aims to bring transformative solutions to the healthcare market, fostering collaboration with healthcare professionals, regulatory agencies, and the broader scientific community. Rexecor's mission is to improve lives through groundbreaking research and the efficient delivery of safe and effective medications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials